Hot Features
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomogra... AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.10005 | -28.099985957 | 0.35605 | 0.35605 | 0.256 | 132 | 0.31610608 | CS |
| 4 | -0.034 | -11.724137931 | 0.29 | 0.35605 | 0.256 | 3951 | 0.26867334 | CS |
| 12 | -0.18685 | -42.1926160099 | 0.44285 | 0.4799 | 0.256 | 3297 | 0.32014768 | CS |
| 26 | -0.53665 | -67.7032738283 | 0.79265 | 0.846 | 0.256 | 2429 | 0.42661142 | CS |
| 52 | -0.351375 | -57.8514097551 | 0.607375 | 2.33 | 0.256 | 3572 | 1.08490389 | CS |
| 156 | -0.614 | -70.5747126437 | 0.87 | 2.33 | 0.2159 | 4911 | 0.70017954 | CS |
| 260 | -1.394 | -84.4848484848 | 1.65 | 3 | 0.2159 | 4908 | 0.81408617 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.